Jupiter Bioscience Ltd
Jupiter Bioscience Limited manufactures drug intermediates, specialty and fine chemicals, bulk drugs, and nutraceuticals primarily in India. The company offers aminoacids and its derivatives, including Fmoc-, Boc-, and Z-protected aminoacids, as well as side chain protected aminoacids.
- Market Cap ₹ Cr.
- Current Price ₹ 3.97
- High / Low ₹ /
- Stock P/E
- Book Value ₹ 137
- Dividend Yield 0.00 %
- ROCE 8.18 %
- ROE 8.14 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.03 times its book value
- Company has delivered good profit growth of 22.8% CAGR over last 5 years
Cons
- Tax rate seems low
- Company has a low return on equity of 9.58% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | |
|---|---|---|---|---|---|---|
| 91 | 121 | 154 | 178 | 233 | 331 | |
| 49 | 70 | 86 | 90 | 113 | 185 | |
| Operating Profit | 42 | 51 | 68 | 88 | 119 | 146 |
| OPM % | 46% | 42% | 44% | 50% | 51% | 44% |
| 0 | 0 | 1 | 2 | 0 | 0 | |
| Interest | 7 | 8 | 13 | 19 | 26 | 29 |
| Depreciation | 12 | 16 | 22 | 33 | 44 | 59 |
| Profit before tax | 23 | 27 | 34 | 38 | 49 | 58 |
| Tax % | 21% | 25% | 14% | 12% | 13% | 12% |
| 18 | 20 | 30 | 33 | 42 | 51 | |
| EPS in Rs | 20.51 | 16.40 | 20.48 | 26.33 | 8.23 | |
| Dividend Payout % | 12% | 11% | 12% | 10% | 9% | 13% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 29% |
| TTM: | 42% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 20% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 10% |
| Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | |
|---|---|---|---|---|---|---|
| Equity Capital | 9 | 10 | 18 | 16 | 18 | 65 |
| Reserves | 107 | 161 | 291 | 319 | 390 | 789 |
| 114 | 180 | 200 | 301 | 427 | 455 | |
| 22 | 21 | 30 | 34 | 37 | 56 | |
| Total Liabilities | 252 | 371 | 539 | 670 | 873 | 1,364 |
| 96 | 143 | 241 | 317 | 408 | 513 | |
| CWIP | 42 | 81 | 123 | 146 | 217 | 259 |
| Investments | 1 | 1 | 1 | 10 | 18 | 301 |
| 114 | 146 | 174 | 198 | 231 | 291 | |
| Total Assets | 252 | 371 | 539 | 670 | 873 | 1,364 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | |
|---|---|---|---|---|---|---|
| 32 | 18 | 48 | 68 | 92 | 118 | |
| -57 | -105 | -163 | -143 | -220 | -514 | |
| 25 | 88 | 115 | 74 | 133 | 395 | |
| Net Cash Flow | 0 | 1 | -0 | -1 | 5 | -2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | |
|---|---|---|---|---|---|---|
| Debtor Days | 81 | 87 | 94 | 102 | 92 | 90 |
| Inventory Days | 190 | 316 | 354 | 418 | 346 | 221 |
| Days Payable | 34 | 35 | 34 | 51 | 50 | 29 |
| Cash Conversion Cycle | 237 | 368 | 413 | 470 | 388 | 282 |
| Working Capital Days | 122 | 190 | 213 | 239 | 225 | 187 |
| ROCE % | 12% | 11% | 10% | 10% | 8% |
Documents
Announcements
No data available.